Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Shares Surge 30 Percent as Revenue Climbs 23 Percent and Firm Swings to Profit

NEW YORK (GenomeWeb News) — Luminex today said fourth-quarter revenue increased 23 percent as R&D spending rose 43 percent as it swung to a profit.
 
News of the earnings caused shares in the company to surge 30 percent, or $3.76, to $16.49 in early-afternoon trading today.
 
Total receipts for the three months ended Dec. 31, 2006, increased to $14.2 million from $11.6 million year over year.
 
R&D spending increased to $2.3 million from $1.6 million year over year.
 
The company said it swung to a profit of $599,000 from a loss of $1.3 million in the year-ago period.
 
Luminex said it had around $27.4 million in cash and equivalents and $11 million in short-term investments as of Dec. 31, 2006.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.